Cargando…
Emerging Medical Treatments for Meningioma in the Molecular Era
Meningiomas are the most common type of primary central nervous system tumors. Approximately, 80% of meningiomas are classified by the World Health Organization (WHO) as grade I, and 20% of these tumors are grade II and III, considered high-grade meningiomas (HGMs). Clinical control of HGMs, as well...
Autores principales: | Nigim, Fares, Wakimoto, Hiroaki, Kasper, Ekkehard M., Ackermans, Linda, Temel, Yasin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165537/ https://www.ncbi.nlm.nih.gov/pubmed/30082628 http://dx.doi.org/10.3390/biomedicines6030086 |
Ejemplares similares
-
Surgical strategies for intracranial meningioma in the molecular era
por: Dincer, Alper, et al.
Publicado: (2023) -
Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules
por: Peters, Cole W. D., et al.
Publicado: (2021) -
Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review
por: Andrade, Pablo, et al.
Publicado: (2010) -
Comparing deep brain stimulation in the ventral intermediate nucleus versus the posterior subthalamic area in essential tremor patients
por: Degeneffe, Aurélie, et al.
Publicado: (2018) -
Emerging systemic treatment options in meningioma
por: Mair, Maximilian J., et al.
Publicado: (2022)